Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL). Methods: Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in bone marrow expressed CD20 ≥ 20% at the time of diagnosis. Patients received multiagent chemotherapy with rituximab. After achieving complete remission (CR), patients received five cycles of consolidation with concomitant rituximab. Rituximab was administered monthly from day 90 of transplantation for patients who received allogeneic hematopoietic cell transplantation. Results: In patients with Philadelphia (Ph)-negative ALL, 39 of 41 achieved CR (95.1%), the 2- and 4-year relapse-free survival (RFS) rates were 50.4% and 35.7%, and the 2- and 4-year overall survival (OS) rates were 51.5% and 43.2%, respectively. In the group with Ph-positive ALL, all 32 patients achieved CR, the 2- and 4-year RFS rates were 60.7% and 52.1%, and the 2- and 4-year OS rates were 73.3% and 52.3%, respectively. In the Ph-negative ALL group, patients with higher CD20 positivity experienced more favorable RFS (p < 0.001) and OS (p = 0.06) than those with lower CD20 positivity. Patients who received ≥ 2 cycles of rituximab after transplantation had significantly improved RFS (hazard ratio [HR], 0.31; p = 0.049) and OS (HR, 0.29; p = 0.021) compared with those who received < 2 cycles. Conclusions: The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials. gov NCT01429610).
Abstract
Background/Aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL). Methods: Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in bone marrow expressed CD20 ≥ 20% at the time of diagnosis. Patients received multiagent chemotherapy with rituximab. After achieving complete remission (CR), patients received five cycles of consolidation with concomitant rituximab. Rituximab was administered monthly from day 90 of transplantation for patients who received allogeneic hematopoietic cell transplantation. Results: In patients with Philadelphia (Ph)-negative ALL, 39 of 41 achieved CR (95.1%), the 2- and 4-year relapse-free survival (RFS) rates were 50.4% and 35.7%, and the 2- and 4-year overall survival (OS) rates were 51.5% and 43.2%, respectively. In the group with Ph-positive ALL, all 32 patients achieved CR, the 2- and 4-year RFS rates were 60.7% and 52.1%, and the 2- and 4-year OS rates were 73.3% and 52.3%, respectively. In the Ph-negative ALL group, patients with higher CD20 positivity experienced more favorable RFS (p < 0.001) and OS (p = 0.06) than those with lower CD20 positivity. Patients who received ≥ 2 cycles of rituximab after transplantation had significantly improved RFS (hazard ratio [HR], 0.31; p = 0.049) and OS (HR, 0.29; p = 0.021) compared with those who received < 2 cycles. Conclusions: The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials. gov NCT01429610).
참고문헌 (32)
- Pui CH, "Acute lymphoblastic leukemia", N Engl J Med, 350, pp.1535~1548 (2004)
- Bassan R, "Adult acute lymphoblastic leukaemia", Crit Rev Oncol Hematol, 50, pp.223~261 (2004)
- Raponi S, "Flow cytometric study of potential target antigens(CD19, CD20, CD22, CD33)for antibody-based immunotherapy in acute lymphoblastic leukemia : analysis of 552 cases", Leuk Lymphoma, 52, pp.1098~1107 (2011)
- Kantarjian H, "Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia : a phase 2 study", Lancet Oncol, 13, pp.403~411 (2012)
- Terwilliger T, "Acute lymphoblastic leukemia : a comprehensive review and 2017 update", Blood Cancer J, 7, pp.e577~ (2017)
- Thomas DA, "Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia", Blood, 113, pp.6330~6337 (2009)
- Czuczman MS, "Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels", Clin Cancer Res, 14, pp.1561~1570 (2008)
- Jazirehi AR, "Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy", Cancer Res, 67, pp.1270~1281 (2007)
- Borowitz MJ, "Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A pediatric oncology group study", Blood, 89, pp.3960~3966 (1997)
- Jeha S, "Prognostic significance of CD20expression in childhood B-cell precursor acute lymphoblastic leukemia", Blood, 108, pp.3302~3304 (2006)
- Kantarjian HM, "Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia", J Clin Oncol, 18, pp.547~561 (2000)
- Kantarjian H, "Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia", Cancer, 101, pp.2788~2801 (2004)
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
- Thomas DA, "Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia", Cancer, 106, pp.1569~1580 (2006)
- Romaguera JE, "High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine", J Clin Oncol, 23, pp.7013~7023 (2005)
- Tam CS, "Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia", Blood, 112, pp.975~980 (2008)
- Thomas DA, "Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia", J Clin Oncol, 28, pp.3880~3889 (2010)
- Maury S, "Rituximab in B-lineage adult acute lymphoblastic leukemia", N Engl J Med, 375, pp.1044~1053 (2016)
- Hoelzer D, "Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults", Blood, 71, pp.123~131 (1988)
- Malard F, "Acute lymphoblastic leukaemia", Lancet, 395, pp.1146~1162 (2020)
- Kim DY, "Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia", Blood, 126, pp.746~756 (2015)
- Dong Won Baek, "Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406", 1407 study, 2021, pp.36(6), 1471~1485[DOI]
- Marks DI, "Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia(UKALL14) : a phase 3, multicentre, randomised controlled trial", Lancet Haematol, 9, pp.e262~e275 (2022)
- Esteban RE, "Prognostic effect of CD20 expression in adult B-cell acute lymphoblastic leukemia", Clin Lymphoma Myeloma Leuk, 18, pp.361~367 (2018)
- Alduailej H, "Outcome of CD20-positive adult B-cell acute lymphoblastic leukemia and the impact of rituximab therapy", Clin Lymphoma Myeloma Leuk, 20, pp.e560~e568 (2020)
- Szczepanowski M, "CD20 expression and response to rituximab treatment in B-cell precursor lymphoblastic leukemia-results of the GMALL 08", 2013 trial, 2018, pp.132(Supplement1), 1409~
- Jabbour E, "Monoclonal antibodies in acute lymphoblastic leukemia", Blood, 125, pp.4010~4016 (2015)
- Dworzak MN, "CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment : setting the stage for anti-CD20directed immunotherapy", Blood, 112, pp.3982~3988 (2008)
- Aldoss I, "Advances in adult acute lymphoblastic leukemia therapy", Leuk Lymphoma, 59, pp.1033~1050 (2018)
- Kaito S, "Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission", Transplant Cell Ther, 28, pp.326~ (2022)
- Willasch AM, "Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL : the Frankfurt experience", Bone Marrow Transplant, 52, pp.201~208 (2017)
- Bazarbachi A, "20-year steady increase in survival of adult patients with relapsed Philadelphia-positive acute lymphoblastic leukemia post allogeneic hematopoietic cell transplantation", Clin Cancer Res, 28, pp.1004~1012 (2022)